100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Disclosure - DEBT - Schedule of Debt (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100060 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100070 - Disclosure - INCOME TAXES - Deferred Taxes (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 100100 - Statement - CONSOLIDATED STATEMENTS OF INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100110 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 100120 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 100130 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - NET INCOME PER SHARE link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - CAPITALIZED FEES PAID link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - BALANCE SHEET COMPONENTS link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - NET INCOME PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - CAPITALIZED FEES PAID (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - BALANCE SHEET COMPONENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - NET INCOME PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - NET INCOME PER SHARE - Basic and Diluted EPS (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - NET INCOME PER SHARE - Anti-Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - REVENUE RECOGNITION (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995995 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details) link:presentationLink link:calculationLink link:definitionLink 996005 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996015 - Disclosure - BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996025 - Disclosure - BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 996035 - Disclosure - STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details) link:presentationLink link:calculationLink link:definitionLink 996045 - Disclosure - STOCK-BASED COMPENSATION - Director Compensation Program (Details) link:presentationLink link:calculationLink link:definitionLink 996055 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 996065 - Disclosure - STOCK-BASED COMPENSATION - Compensation Awards (Details) link:presentationLink link:calculationLink link:definitionLink 996075 - Disclosure - STOCK-BASED COMPENSATION - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 996085 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 996095 - Disclosure - DEBT - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 996105 - Disclosure - DEBT - Convertible Subordinated Notes (Details) link:presentationLink link:calculationLink link:definitionLink 996115 - Disclosure - DEBT - Convertible Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 996125 - Disclosure - DEBT - Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 996135 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 996145 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details) link:presentationLink link:calculationLink link:definitionLink 996155 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details) link:presentationLink link:calculationLink link:definitionLink 996165 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 996175 - Disclosure - INCOME TAXES - Income tax expense (Details) link:presentationLink link:calculationLink link:definitionLink 996185 - Disclosure - INCOME TAXES - Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 996195 - Disclosure - INCOME TAXES - Deferred Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 996205 - Disclosure - INCOME TAXES - Additional Tax Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 996215 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Increase to convertible notes. Increase To Convertible Notes Increase in convertible notes Goodwill [Line Items] Auditor Firm ID Increase (Decrease) in Interest Payable, Net Accrued interest payable The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate Debt Conversion, Converted Instrument, Average Trade Price Percentage Average trading price percentage 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Arrangements and Non-arrangement Transactions [Domain] Document Transition Report Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term of options outstanding Interest Expense, Debt [Abstract] Interest expense Money Market Funds [Member] Money market funds Capitalized Contract Cost [Abstract] Transaction costs to acquire equity securities Payments of Stock Issuance Costs Equity issuance costs Interest on Convertible Debt, Net of Tax Add: interest expense on Notes, net of tax effect Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales. Collaborative Arrangement, Royalty Rate Defined, Level Two Royalty rate for sales above first level of annual global net sales (as a percent) Obligation to pay royalties Accrued Royalty Obligations Obligations incurred through that date and payable for royalties. Geographical [Axis] Unrealized Gain (Loss) on Investments, Total Unrealized Gain (Loss) on Investments Unrealized loss on other equity investments Changes in fair values of other equity and long-term investments, net Noncontrolling Interest [Member] Noncontrolling Interest Cost of license revenue Cost of Revenue Cost of Revenue, Total Debt Securities, Available-for-sale, Total Debt Securities, Available-for-Sale Estimated Fair Value Receivables, Long-Term Contracts or Programs Receivables from collaboration arrangements Other Liabilities, Noncurrent Other long-term liabilities Total other long-term liabilities Restricted Stock Units (RSUs) [Member] RSUs Future amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two Fair Value, Inputs, Level 1 [Member] Quoted Price in Active Markets for Identical Assets, Level 1 Entity Public Float The number of tranches in which the Company agreed to purchase common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement. Securities Purchase Agreement, Number of Tranches Number of tranches Number of tranches Weighted Average [Member] Weighted-average Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument that was repurchased. Debt Instrument, Ratio of repurchase price to the principal amount Ratio of repurchase price to the principal amount Income Tax, Policy [Policy Text Block] Income Taxes Property, Plant and Equipment, Useful Life Estimated useful life Total royalty revenue License revenue Revenue from Contract with Customer, Excluding Assessed Tax Total revenue Total net revenue Interest Expense, Borrowings, Total Interest Expense, Borrowings Interest expense Equity method investments Equity Method Investment Equity method investment. Customer two. Customer Two [Member] Customer Two Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation cost Disaggregation of Revenue [Table Text Block] Schedule of net revenue from collaborative arrangements Concentration Risk Type [Axis] Short-Term Debt, Type [Axis] ICFR Auditor Attestation Flag Schedule of Business Acquisitions, by Acquisition [Table] Describes the entity's accounting policies for transactions entered with related parties. Related Party Transactions [Policy Text Block] Related Parties Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Capped call options associated with convertible senior notes due 2028 Inventory fair value step-up adjustment included in cost of products sold Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales Inventory fair value step-up adjustment included in cost of product sales. Gross amount of In-process research and development. Intangible Assets In-process Research and Development, Gross In-process research and development, gross carrying amount Schedule of income taxes. Income Taxes [Table] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of stock-based compensation expense included in the consolidated statements of operations by award type Title of Individual [Domain] Relationship to Entity [Domain] Subsequent Events [Text Block] SUBSEQUENT EVENTS Risk free interest rate. Risk Free Interest Rate Risk free interest rate Convertible Debt, Fair Value Disclosures 2028 Notes Purchase of entasis noncontrolling interest. Purchase Of Entasis noncontrolling Interest Purchase of Entasis noncontrolling interest Operating Lease, Liability, Noncurrent Long-term portion of lease liabilities Deferred royalty obligations Deferred Royalty Obligations Deferred royalty obligations. Initial contribution Limited Partners Initial Contribution Limited partners initial contribution. Represents the number of derivative instruments purchased. Number of Derivative Instruments Purchased Number of derivative instruments purchased Claim expiration date. Claim Expiration Date No definition available. Net Income (Loss) Per Share [Abstract] Net income per share attributable to Innoviva stockholders Noncontrolling Interest, Period Increase (Decrease), Total Noncontrolling Interest, Period Increase (Decrease) Measurement period adjustments for change in value of noncontrolling interests Europe [Member] Europe Net Income (Loss) Attributable to Noncontrolling Interest, Total Net Income (Loss) Attributable to Noncontrolling Interest Net loss attributable to noncontrolling interests Net loss attributable to noncontrolling interests Treasury stock: at cost, 32,005 shares as of December 31, 2023 and 2022 Treasury Stock, Common, Value Debt Securities, Available-for-Sale [Table] Health care royalty partners member. Health Care Royalty Partners [Member] HealthCare Royalty Partners Payment for management and annual performance incentive fees Payment of Management and Incentive fee Payment of management and Incentive fee Liabilities, Fair Value Disclosure Total liabilities measured at estimated fair value Total liabilities at estimated fair value Assets, Fair Value Disclosure [Abstract] Assets Represents information pertaining to common stock and warrants. Common Stock And Warrants [Member] Common stock and warrants Debt Instrument, Unamortized Discount, Total Debt Instrument, Unamortized Discount Unamortized Debt discount Non cash activity. Non Cash Activity Adoption of ASU 2020-06 Schedule of Goodwill [Table] Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired. Cash Paid for the Acquisition of La Jolla Pharmaceutical Company, Net of Cash Acquired Cash paid for the acquisition of La Jolla, net of cash acquired Stock-based compensation (in shares) Adjustments to additional paid in capital share based compensation requisite service period recognition shares. Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares Reduction to additional paid in capital Reduction to Additional Paid in Capital Reduction to Additional Paid in Capital Series D 1 preferred stock member. Series D 1 Preferred Stock [Member] Series D 1 Preferred Stock Derecognition of noncontrolling interestsupon sale of TRC. Derecognition of Noncontrolling Interests Upon Sale of TRC Derecognition of noncontrolling interests upon sale of TRC Balance Sheet Location [Axis] Assets, Current Current assets Total current assets Description of Operations Description of Operations [Policy Text Block] Description of operations. Liabilities and Equity Total liabilities and stockholders' equity Dividend yield. Dividend Yield Entity Address, State or Province Deferred Tax Assets, Other Other Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred Amount of cash distribution received. Cash Distribution Received Cash distribution Royalty agreement, maximum potential payout, percent. Royalty Agreement Maximum Potential Payout Percent Maximum potential royalty payout Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Name Of Event [Domain] Name Of Event [Domain] Represents information pertaining to Burlingame, California. Burlingame California [Member] Burlingame, California Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average estimated fair value of shares granted (in dollars per share) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income attributable to Innoviva stockholders AstraZeneca AstraZeneca [Member] AstraZeneca. Goodwill and Intangible Assets, Policy [Policy Text Block] Goodwill and Intangible Assets Trading Symbol Deferred Tax Assets, Net of Valuation Allowance Total deferred tax assets Payment of Financing and Stock Issuance Costs, Total Payment of Financing and Stock Issuance Costs Total issuance costs Common Stock, Shares, Issued, Total Common Stock, Shares, Issued Common stock, shares issued Debt Securities, Available-for-Sale [Line Items] Available-for-Sale Securities 2025 Long-Term Debt, Maturity, Year Two Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total estimated fair value of equity instruments vested Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of Components of Interest Expense Consolidated investees. Consolidated Investees [Member] Consolidated Investees Percentage of estimated volatility. Percentage of Estimated Volatility Estimated volatility Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses Right of Use Assets Obtained Through Acquistions Right of Use Assets Obtained Through Acquistions Right-of-use assets obtained through acquisitions Consolidated Entities [Domain] Consolidated Entities [Domain] Equity Method Investments [Policy Text Block] Equity and Long-Term Investments Schedule Of Balance sheet Information Related To Operating Lease Table Text Block Schedule Of Balance sheet Information Related To Operating Lease Table Text Block Schedule of Operating Lease Information Presented In Balance Sheet Accounts Receivable, after Allowance for Credit Loss, Total Accounts Receivable, after Allowance for Credit Loss Accounts receivable Two Directors. Two Directors [Member] Two Directors Unrealized Gain on Investment, net Deferred Tax Liabilities, Investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Accounts receivable Schedule of Long-Term Debt Instruments [Table] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Common Stock, Capital Shares Reserved for Future Issuance Common Stock, Capital Shares Reserved for Future Issuance Subsidiary or Equity Method Investee [Line Items] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Maximum number of shares an employee may purchase during any purchase period Components of Deferred Tax Liabilities [Abstract] Deferred tax liabilities Balance sheets No definition available. Balance Sheet Disclosures of Variable Interest Entity [Abstract] Long-Term Debt, Current Maturities Net Carrying Amount Convertible Promissory Note Purchase Agreement [Member] Convertible promissory note purchase agreement [Member] Convertible Promissory Note Purchase Agreement Entity Address, City or Town Related Party Transaction [Line Items] Related Parties Represents the consecutive and overlapping offering period for the offering of share-based payment awards. Share Based Compensation Arrangement by Share Based Payment Award Consecutive and Overlapping Offering Period Total duration of consecutive and overlapping offering periods Cost reimbursements Cost Reimbursements Cost reimbursements Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Incremental Common Shares Attributable to Conversion of Debt Securities, Total Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Dilutive effect Increase (Decrease) in Income Taxes Payable Income tax payable Debt Disclosure [Text Block] DEBT Distributions to noncontrolling interest (in shares) Minority interest decrease from distributions to noncontrolling interest holders shares. Minority Interest Decrease From Distributions To Noncontrolling Interest Holders Shares Subsequent Event [Member] Subsequent Event Subsequent Event Type [Axis] Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Net increase in tax portions Laboratory equipment, furniture and fixtures. Laboratory Equipment, Furniture And Fixtures [Member] Laboratory equipment furniture and fixtures Everest Medicines Limited [Member] Everest Medicines Limited [Member] Everest Medicines Limited Additional Paid-in Capital [Member] Additional Paid-In Capital Schedule of components of the income tax expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Non-US [Member] Rest of the world Business Acquisition, Pro Forma Revenue Revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Inventory Liabilities, Current [Abstract] Current liabilities: Waltham Massachusetts Member Waltham Massachusetts Member Cash Acquired from Acquisition Cash acquired through the consolidation of Entasis Other Accrued Liabilities [Member] Other Accrued Liabilities [Member] Other Accrued Liabilities Assets, Current [Abstract] Current assets: Counterparty Name [Axis] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Statement of Stockholders' Equity [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest at the end of the period (in dollars per shares) Operating Lease, Liability, Current Current portion of lease liabilities included within Other accrued liabilities Current portion of lease liabilities Marketable Securities, Policy [Policy Text Block] Investments in Marketable Securities Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Conversion of convertible subordinated notes due 2023 Debt instrument maturity date Debt Instrument, Maturity Date Debt instrument maturity date Long-Term Debt Net carrying amount Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net Property and equipment, net Increase (Decrease) in Deferred Income Taxes Income tax expense recognized Schedule of Balance Sheets and Income Statements of VIE Schedule of Variable Interest Entities [Table Text Block] Deferred tax liabilities inventory fair value adjustment Deferred Tax Liabilities Inventory Fair Value Adjustment Inventory fair value adjustment Investment Income, Interest Investment Income, Interest Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards. Share Based Compensation Arrangement by Share Based Payment Award Purchase Period Duration of purchase period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Intangible assets Disclosure of accounting policy for reporting prior period immaterial correction. Prior Period Immaterial Correction [Policy Text Block] Prior Period Immaterial Correction Loans Payable [Member] Loans Payable [Member] Statement of Comprehensive Income [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Treasury stock, shares Treasury Stock, Common, Shares CIK Entity Central Index Key Convertible note and warrants. Convertible Note and Warrants [Member] In Carda Convertible Note Convertible note and warrants Number of Investee's Board members currently representing the Company Number of the Company's Board Members Currently Serving on the Board of Investee The number of the Company's Board members currently serving on the Investee's Board. Plan Name [Domain] Plan Name [Domain] Commercial supply agreement. Commercial Supply Agreement [Member] Commercial Supply Agreement Assets, Fair Value Disclosure Total assets measured at estimated fair value Assets, Fair Value Disclosure, Total Increase (Decrease) in Other Operating Assets, Total Increase (Decrease) in Other Operating Assets Other assets Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures Forfeited (in shares) Regulatory milestone payments receivable. Regulatory Milestone Payments Receivable Additional regulatory milestone payments receivable Accumulated amortization amount of Marketed Products. Intangible Assets Marketed Products, Accumulated Amortization Marketed products, Accumulated amortization The percentage above the last reported sale price of the Company's common stock. Debt Instrument, Convertible, Conversion Premium Conversion premium (as a percent) Liabilities, Current Current liabilities Total current liabilities Current liabilities Entity Tax Identification Number Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income taxes Inventory, Finished Goods, Net of Reserves Finished goods Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Payments of Debt Issuance Costs Liability issuance costs Financial Instruments [Domain] Financial Instruments [Domain] Percentage of reimbursed for direct and certain indirect manufacturing costs. Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs Percentage of reimbursed for direct and certain indirect manufacturing costs Represents Long-Acting Beta2 Agonist, RELVAR/BREO, which is being developed and commercialized by entering into a strategic alliance with GSK Long Acting Beta2 Agonist Relvar Breo [Member] RELVAR/BREO Investment, Name [Axis] Debt Instrument, Term Debt instrument, term Income Tax Examination, Penalties and Interest Accrued, Total Income Tax Examination, Penalties and Interest Accrued Accrued interest and penalties Restricted Stock [Member] RSAs Represents information pertaining to the variable interest entity, Theravance Respiratory Company, LLC ("TRC"). Theravance Respiratory Company Llc [Member] Theravance Respiratory Company, LLC Plan Name [Axis] Represents the number of purchase periods having duration of six months each. Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods Number of offering periods ImaginAb Convertible Note ImaginAb Convertible Note [Member] ImaginAb Convertible Note. Geographical [Domain] Geographical [Domain] Lessee, Operating Lease, Term of Contract Lease term Assets Total assets Total assets Recognition of noncontrolling interest upon initial consolidation of Entasis (in shares) Recognition Of Noncontrolling Interest Upon Initial ConsolidationOf Entasis, Shares Recognition of noncontrolling interest upon initial consolidation of Entasis, Shares. UNITED STATES United States Operating Lease, Right-of-Use Asset Right-of-use assets Series D 2 preferred stock member. Series D 2 Preferred Stock [Member] Series D 2 Preferred Stock Net operating loss carryforwards which can be carry forward indefinitely. Operating Loss Carryforwards, Indefinite Period Net operating loss carryforwards, indefinite period Royalty Payments Royalty Payments Royalty Payments Registrant Name Entity Registrant Name Components of Deferred Tax Assets [Abstract] Deferred tax assets Proceeds from Issuance or Sale of Equity, Total Proceeds from Issuance or Sale of Equity Gross Proceeds from sale of equity Lessee, Lease, Description [Line Items] Operating Lease Related Party, Type [Domain] Related Party [Domain] Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit) Accumulated deficit Long-Term Debt, Fiscal Year Maturity [Abstract] Long-term debt maturities for years ending December 31: LLC members' equity Members' Equity Members' Equity, Total Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Retained Earnings [Member] Accumulated Deficit Inventory, Raw Materials, Net of Reserves Raw materials Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total stockholders' equity Accrued contract manufacturing liability. Accrued Contract Manufacturing Liability Accrued contract manufacturing expenses Amount of accrued personnel-related expenses due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Personnel- Related Expenses Accrued personnel-related expenses Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Expected tax at federal statutory rate Deferred Income Tax Liabilities, Net Deferred tax liabilities, net Net deferred tax (liabilities) Minimum [Member] Minimum Gross amount of Marketed products. Intangible Assets Marketed Products, Gross Marketed products, gross carrying amount The percentage of ownership of common stock in the reporting entity owned by related parties. Related Party Transaction, Common Stock Ownership Percentage By Related Party Percentage of common stock owned by a related party Derecognition of noncontrolling interests upon sale of TRC (in shares) Derecognition Of Noncontrolling Interests Upon Sale Of Trc Shares Derecognition of noncontrolling interests upon sale of trc shares. Revenue Revenues, Total Revenues Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Operating Lease, Liability Total operating lease liabilities Total operating lease liabilities Liabilities, Fair Value Disclosure [Abstract] Liabilities Revenue [Policy Text Block] Revenue Recognition Derecognition of non controlling interests upon acquisition of entasis minority interest. Derecognition Of Non Controlling Interests Upon Acquisition Of Entasis Minority Interest Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest Accrued Income Taxes, Current Income tax payable Armata Convertible Note Armata Convertible Note [Member] Armata convertible note member. Equity Component [Domain] Equity Component [Domain] Reduction to Research and Development Expense Reduction to Research and Development Expense Reduction to research and development expense Share repurchase agreement with GSK Share Repurchase Agreement With Glaxo Group Limited [Member] Represents information pertaining to share repurchase agreement with Glaxo Group Limited. Information related to warrants acquired in the second quarter of 2021 Warrants Acquired In Second Quarter Of2021 [Member] Warrants acquired in second quarter of 2021 Amortization of Debt Issuance Costs and Discounts, Total Amortization of Debt Issuance Costs and Discounts Amortization of debt discount and issuance costs Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Valuation Assumptions Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Equity Investment Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Less: Unamortized debt discount and issuance costs Debt discount and issuance costs, net Debt discount and issuance costs, net Measurement Frequency [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price of Outstanding Options Debt Disclosure [Abstract] Net Income (Loss) Available to Common Stockholders, Diluted Net income attributable to Innoviva stockholders, diluted Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Entity Current Reporting Status Common Stock, Shares Authorized Common stock, shares authorized Put Option [Member] Stock prices above $38.00 per share Research and Development Expense, Total Research and Development Expense Research and development Accrued Clinical Liability Accrued Clinical Liability Accrued clinical expenses Percentage of minimum royalty rate. Percentage Of Minimum Royalty Rate Percentage of minimum royalty rate Fair Value, by Balance Sheet Grouping [Table] Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement. Collaborative Arrangement, Specified Sales Level for Determining Royalty Rate Annual global sales level used to determine royalty rate Deferred Tax Liabilities, Gross Net deferred tax (liabilities) Net deferred tax (liabilities) The maximum number of additional common stock shares into which the warrants may be converted. Securities Purchase Agreement, Warrants, Number of Securities Called by Warrants Maximum number of additional shares into which warrants may be converted under the securities purchase agreement Maximum number of additional shares into which warrants may be converted under the securities purchase agreement Debt Conversion, Converted Instrument, Amount Notes converted into common stock, Amount Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Changes to noncontrolling interest from a consolidated variable interest entity. Changes to noncontrolling interest from a consolidated variable interest entity Equity activity of noncontrolling interest in a consolidated variable interest entity Represents the number of shares payable to the entity on settlement of derivative instruments. Number of Shares Receivable on Settlement of Derivative Instrument Net shares settlement payable to the entity Share-Based Payment Arrangement, Activity [Table Text Block] Summary of equity award activity and related information Assets [Abstract] Assets Accounting Standards Update [Extensible Enumeration] Proceeds from issuances of common stock, net Proceeds from Issuance of Common Stock Amortization of Intangible Assets Amortization of acquired intangible assets Amortization expense Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Net Income Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares remaining available for issuance Accrued interest income added to long-term investments Accrued Interest Income Included in Long-term Investments Accrued interest income included in long-term investments. Stock Repurchased and Retired During Period, Value Stock repurchased and retired during period, value Series D1 Warrant [Member] Series D1 Warrant [Member] Series D1 Warrant Common stock: $0.01 par value, 200,000 shares authorized, 69,307 and 69,188 issued and outstanding as of December 31, 2023 and December 31, 2022 respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Debt Instrument, Convertible, Conversion Price Conversion price (dollars per share) Conversion price of convertible notes into common stock (in dollars per share) Other Noncash Income (Expense), Total Other Noncash Income (Expense) Other non-cash items Deconsolidation, Gain (Loss), Amount Net gain on sale of TRC Net gain on sale of TRC Gain on sale of Theravance Respiratory Company, LLC ("TRC") Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cash and cash equivalents Current Fiscal Year End Date Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Auditor Name Operating Income (Loss) Income from operations Loss from operations Operating expenses Royalty payments Repayments of Debt XERAVA. XERAVA [Member] XERAVA License and collaboration arrangements disclosure. License and Collaboration Arrangements Disclosure [Text Block] LICENSE AND COLLABORATION ARRANGEMENTS Business Combination, Consideration Transferred Total consideration paid Total consideration paid Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELVAR. Laba Collaboration [Member] Long-Acting Beta2 Agonist (LABA) Collaboration Deferred Income Tax Expense (Benefit), Total Deferred Income Tax Expense (Benefit) Deferred income taxes Total income tax expense, net Total income tax expense, net Income tax expense, net Income tax expense, net Income Tax Expense (Benefit) Income tax expense, net Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Other Research and Development Expense [Member] Research and development 2027 Long-Term Debt, Maturity, Year Four Net decrease in tax portions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Lessee, Leases [Policy Text Block] Operating Leases Royalty [Member] Royalty revenue Royalty revenue from a related party Concentration Risk, Percentage Concentration Risk, Percentage Share-Based Payment Arrangement, Expense Total stock-based compensation expense Payment, Tax Withholding, Share-Based Payment Arrangement Repurchase of shares to satisfy tax withholding Loan Restructuring Modification [Domain] Disaggregation of Revenue [Table] Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount Noncontrolling Interest Series D2 Warrant. Series D2 Warrant [Member] Series D2 Warrant Deferred tax liabilities depreciation and amortization Deferred Tax Liabilities Depreciation and Amortization Depreciation and amortization Deferred Revenue, Total Deferred Revenue Deferred revenue Valuation Approach and Technique [Domain] Revenue from Contract with Customer [Text Block] REVENUE RECOGNITION Unrealized gain loss from fair value changes in equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) Equity Securities, FV-NI, Unrealized Gain (Loss), Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value of options outstanding License License [Member] Convertible notes Face Value Debt Instrument, Face Amount New principal amount convertible note Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Change in valuation allowance Represents information pertaining to Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections. Armata Pharmaceuticals Inc [Member] Armata Cumulative Effect, Period of Adoption, Adjustment [Member] Cumulative effect period of adoption adjustment member Represents information pertaining to equity investments and money market funds. Equity Investments And Money Market Funds [Member] Equity investments and Money market funds Subscription agreement one-time milestone payment on first commercial sale Subscription Agreement One-time Milestone Payment on Commercial Sales Subscription agreement one-time milestone payment on commercial sales. Other expense, net Other income, net Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Other expense, net Capitalized Contract Cost [Table] Income Statement Related Disclosures [Abstract] Income Statement Information Loss Contingency, Allegations Complaints filed by stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive income attributable to noncontrolling interests Operating Expenses [Abstract] Expenses: Property, Plant and Equipment [Abstract] Long-Term Debt, Type [Domain] Long-term Debt, Type [Domain] Credit and Security Agreement Credit and Security Agreement [Member] Credit and security agreement. Entity Voluntary Filers Subsequent Events [Abstract] Debt Securities, Available-for-Sale [Table Text Block] Schedule of amortized cost and estimated fair values for available-for-sale securities Capitalized Contract Cost [Line Items] Capitalized Fees paid The amount of net income (loss) for the period available to convertible notes. Dilutive EPS of Notes Dilutive EPS of note Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Differences between the expected U.S. federal statutory income tax to income tax expense Commitments and Contingencies Disclosure [Abstract] Other Assets, Noncurrent, Total Other Assets, Noncurrent Other assets Warrants purchased in 2022 member. Warrants Purchased In 2022 [Member] Warrants Purchased in 2022 Number of the Investee's Board members Number of Board Members of the Investee The total number of Board members of the Investee. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted (in shares) Equity [Text Block] STOCKHOLDERS' EQUITY Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Note amendment agreement member. Note Amendment Agreement [Member] Note Amendment Agreement Convertable promissory note Convertible Promissory Note [Member] Convertible promissory note member. Future amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Future amortization expense, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Changes in fair value of equity and long-term investments, net Gain loss on other investments. Gain (Loss) on Other Investments Changes in fair value of other equity and long-term investments, net Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Series A1 preferred stock member. Series A1 preferred stock [Member] Series A1 preferred stock Entasis Lease [Member] Entasis Lease [Member] Entasis Lease Equity, Attributable to Parent [Abstract] Stockholders' equity: Series D Preferred Stock [Member] Series D Preferred Stock Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Lease, Cost [Table Text Block] Schedule of Components of Lease Cost Deferred Federal, State and Local, Tax Expense (Benefit) Total Total deferred All Entities Entity [Domain] Line of Credit Facility, Maximum Borrowing Capacity Term loan facility in aggregate amount Schedule of consolidated entities and business acquisitions by acquisition. Schedule of Consolidated Entities and Business Acquisitions by Acquisition [Table] Capitalized fees paid. Capitalized Fees Paid [Policy Text Block] Capitalized Fees Paid Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Total estimated fair value of options vested Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets) Cost of Goods and Services Sold Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets) Lease Contractual Term [Domain] Outstanding stock warrant member Outstanding Stock Warrant [Member] Outstanding Stock Warrant Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Supplemental Cash Flow Information Related to Leases Earnings Per Share [Abstract] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Future Minimum Lease Payments Payments For Royalty Agreement Payments For Royalty Agreement Payment for royalty agreement Represents the strategic alliance with GSK for initiating three new full discovery programs and giving GSK option to license exclusive development and commercialization rights of products. Strategic Alliance Agreement [Member] Strategic alliance - MABA program Investment, Name [Domain] Represents the capped call option entered in connection with the offering of convertible debt. Privately Negotiated Capped Call Option [Member] Privately-negotiated capped call option Future amortization expense, 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Five Lessee, Lease, Description [Table] In Process Research and Development [Member] In-process research and development Represents information pertaining to Entasis Therapeutics Holdings Inc. Entasis Therapeutics Holdings Inc [Member] Entasis Entasis Therapeutics Holdings Inc Deferred tax assets deferred royalty obligation, net Deferred Tax Assets Deferred Royalty Obligation, Net Deferred royalty obligation, net Accrued Professional Services Accrued Professional Services Accrued professional services Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of Credit Risk and of Significant Suppliers and Partners Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-based compensation Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Prepaid expenses Intangible assets collaboration agreement net. Intangible Assets Collaboration Agreement Net Collaboration agreement, net carrying amount Business Acquisition, Pro Forma Information [Table Text Block] Pro Forma Information Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Total assets acquired, net Debt Instrument, Interest Rate, Effective Percentage Effective interest rate Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Distributions to noncontrolling interests Maximum number of additional shares into which warrants may be converted under the securities purchase agreement Sale of Warrants, Number of Warrants Issued in Transaction The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction. Number of warrants purchased under the securities purchase agreement Net Proceeds from sale of variable interest entity equity. Net Proceeds from Sale of Variable Interest Entity Equity Proceeds from sale of ownership interest in TRC, net Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest (in shares) Derecognition Of NonControlling Interests Upon Acquisition Of Entasis Minority Interest Shares Derecognition of nonControlling interests upon acquisition of entasis minority interest shares. Equity Method Investment, Other than Temporary Impairment Impairment of equity investments Intangible assets collaboration agreement gross. Intangible Assets Collaboration Agreement Gross Collaboration agreement, gross carrying amount Earnings Per Share, Basic, Total Earnings Per Share, Basic Basic net income per share attributable to Innoviva stockholders Basic net income per share Current portion of deferred royalty obligation. Deferred Royalty Obligation, Current Current portion of deferred royalty obligation Customer Concentration Risk [Member] Customer Concentration Risk Commitments and Contingencies Commitments and contingencies (Note 13) Section 250 deduction Effective Income Tax Rate Reconciliation, Deduction, Other, Amount Income Statement [Abstract] Net decrease in tax portions for 2021 Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions, Net Net amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return. Ownership interest in consolidated entities. Ownership Interest in Consolidated Entities Ownership interest in LLC Debt, Current, Total Debt, Current Less: Current portion of long-term debt, net Related Party, Type [Axis] Proceeds from sale of economic interest under Equity Purchase Agreement. Proceeds from sale of economic interest under Equity Purchase Agreement Proceeds from sale of economic interest under Equity Purchase Agreement Represents information pertaining to warrants purchased in 2020. Warrants Purchased In2020 [Member] Warrants purchased in 2020 Straight line operating lease costs Operating Lease, Cost Increase (Decrease) in Prepaid Expense Prepaid expenses Prepaid expenses Series D Warrants Series D Warrants [Member] Series D warrants. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest at the end of the period (in shares) Statistical Measurement [Domain] Range [Domain] Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Proceeds from Issuance of Debt Proceeds from issuance of convertible senior notes due 2028, net of issuance costs Schedule of Variable Interest Entities [Table] Period End Date Document Period End Date Statistical Measurement [Axis] Acquisition Costs, Period Cost Acquisition-related costs Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Research and Development Support [Member] Research and Development Support [Member] Research and Development Support Operating Lease, Payments Cash paid for amounts included in the measurement of operating lease liabilities: Share Repurchase Program [Axis] Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Diluted net income per share attributable to Innoviva stockholders Diluted net income per share Unrecognized tax benefits increase resulting from current period tax positions Net Unrecognized Tax Benefits Increase Resulting From Current Period Tax Positions Net Net increase in tax portions for 2022 Carrying value wrote off warrant exercise Carrying Value Wrote off Warrant Exercise Carrying value wrote off warrant exercise. Product and Service [Domain] Products and Services [Domain] Lease, Cost [Abstract] Deferred Tax Assets, Operating Loss Carryforwards, Total Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carryforwards Unrecognized Tax Benefits, Ending Balance Unrecognized Tax Benefits, Beginning Balance Unrecognized Tax Benefits Unrecognized tax benefits Unrealized loss from fair value changes in equity investments Unrealized loss from fair value changes in equity investments Equity Securities, FV-NI, Unrealized Loss Unrealized loss Concentration Risk Benchmark [Domain] The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board. Share Based Compensation, Arrangement by Share Based Payment Award, Additional Equity Grant Value Pro rata shares grant, value Revenue from Contract with Customer [Abstract] Revenue: Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees. Gross Revenue from Contract with Customer, Excluding Assessed Tax, Before Amortization Of Capitalized Fees Royalties Special Terms on amended and restated investor rights agreement. Special Term Re Designating Board Member To Board Of Investee Special terms on re-designating board member to board of investee Payments to Noncontrolling Interests Distributions to noncontrolling interest Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans. Equity Incentive Plans And E S P P [Member] Equity incentive plans and ESPP Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy [Domain] Net amount of In-process research and development. Intangible Assets In-process Research and Development, Net In-process research and development, net carrying amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable option Interest Expense, Policy [Policy Text Block] Interest Expense on Deferred Royalty Obligation Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Volatility Debt instrument, description Debt Instrument, Description Fair Value, Recurring [Member] Recurring basis Term Loan Investment Term Loan Investment [Member] Term loan investment. Capped call options associated with convertible senior notes due 2028 (in shares) Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt in Shares Adjustments to additional paid in capital equity component of convertible debt in shares. Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock Additional paid-in capital Inventory, Policy [Policy Text Block] Inventory Decrease to accumulated deficit. Decrease to Accumulated Deficit Decrease to accumulated deficit Aggregate Scheduled Maturities of Convertible Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Equity Securities, FV-NI, Realized Gain (Loss), Total Equity Securities, FV-NI, Realized Gain (Loss) Remeasurement loss Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of outstanding options Deferred Tax Assets, Net Net deferred tax assets Accrued license fees and royalties Accrued License Fees and Royalties Accrued license fees and royalties Components of Deferred Tax Assets and Liabilities [Abstract] Components of deferred tax assets and deferred tax liabilities Equity Securities, FV-NI, Current Equity and long-term investments at fair value Fair value of equity securities Debt Instrument Principal Amount Debt Instrument Principal Amount Total debt Principal Payments for Repurchase of Common Stock Repurchase of common stock Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity. Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Number Vested and expected to vest at the end of the period (in shares) Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity Attributable to Noncontrolling Interest, Total Equity, Attributable to Noncontrolling Interest Noncontrolling interests Finite-Lived Intangible Assets, Major Class Name [Domain] Realized loss Realized Loss Realized loss Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercised (in shares) Consolidation, Policy [Policy Text Block] Principles of Consolidation Income statements No definition available. Income Statement Disclosures of Variable Interest Entity [Abstract] Liabilities and Stockholders Equity Liabilities and Equity [Abstract] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities [Table Text Block] Schedule of Other Long-term Liabilities Sale of equity investments managed by ISP FUND LP Sale of equity investments managed by ISP FUND LP Sales of equity investments managed by ISP Fund LP The total number of shares to be purchased under the terms of a securities purchase agreement. Securities Purchase Agreement, Total Number of Shares To Be Purchased Under the Agreement Securities to be purchased Number of shares to be purchased under the securities purchase agreement Entity Address, Postal Zip Code Debt Instrument, Convertible, Conversion Ratio Conversion rate for shares of common stock per $1,000 principal Entity Interactive Data Current Private Placement [Member] Private Placement Represents information pertaining to the Company's Employee Stock Purchase Plan (the "ESPP"). Employee Stock Purchase Plan [Member] ESPP Old debt instrument interest rate before repurchase of notes member. Old Debt Instrument Interest Rate Before Repurchase Of Notes [Member] Old Rate [Member] Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits would affect the effective income tax rate if recognized Over-Allotment Option [Member] Over-Allotment Option Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Future amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis Recognition of noncontrolling interest upon initial consolidation of Entasis Equity [Abstract] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Less: imputed interest Entity Well-known Seasoned Issuer Business Acquisition, Pro Forma Net Income (Loss) Net income Business acquisition, net loss Rule 10b51Arrangement Modified Rule 10b51 Arr Modified Flag Rule 10b51 Arr Modified Flag. Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance Debt Securities, Available-for-sale, Allowance for Credit Loss, Total Debt Securities, Available-for-Sale, Allowance for Credit Loss Credit loss The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Entity Incorporation, State or Country Code Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Royalty agreement increase in maximum potential payout percent. Royalty Agreement Increase In Maximum Potential Payout Percent Increase in maximum potential payout percent Value of net fair value adjustment of inventory resulting from the acquisition. Fair Value Adjustments Of Inventory From Acquistion Net fair value adjustment of inventory Represents information pertaining to Trelegy Ellipta. Trelegy Ellipta [Member] TRELEGY Equity Components [Axis] Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Schedule of unrecognized stock-based compensation cost Economic interest of the Partnership (in percent) Percentage of economic interest held in Partnership. Percentage of Economic Interest In Partnership Increase (Decrease) in Accounts Receivable Accounts receivable, net Accounts receivable Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Convertible Subordinated Debt, Fair Value Disclosures 2023 Notes Inventory Disclosure [Abstract] Distribution from partnership Limited Partners' Cumulative Cash Distributions Option Pricing Model Backsolve valuation. Option Pricing Model Backsolve Valuation [Member] Backsolve Valuation Accrued Research Liability Accrued Research Liability Accrued research expenses Interest Expense, Borrowings [Abstract] Interest expense Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Released RSUs and RSAs (in dollars per share) Local Phone Number Property, Plant and Equipment [Line Items] Property, equipment and leasehold improvements Sale of Stock [Axis] The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement. Partnership Agreement, Lock-Up Period Lock-up period Debt Conversion, Converted Instrument, Shares Issued Debt Conversion, Converted Instrument, Shares Issued Increase (Decrease) in Deferred Revenue Deferred revenue Current Federal Tax Expense (Benefit) Federal Research Tax Credit Carryforward [Member] Research and development Goodwill, Total Goodwill, Beginning Balance Goodwill, Ending Balance Goodwill Goodwill Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment. Convertible Senior Debt, Fair Value Disclosures 2025 Notes Line of Credit Facility, Covenant Terms Debt instrument, covenant terms description Increase (decrease) in deferred tax assets Increase (Decrease) In Deferred Tax Assets Increase (Decrease) in deferred tax assets. Statement of Cash Flows [Abstract] Capitalized Contract Cost [Table Text Block] Schedule of Capitalized Fees Paid Comprehensive Income, Policy [Policy Text Block] Comprehensive Income The number of the investee's board members which the Company has the right to designate. Securities Purchase Agreement Rights To Designate Investee Board Members Number Of Board Members Number of investee's board members which may be designated by the Company Director [Member] Non-employee director Stock Repurchased and Retired During Period, Shares Stock repurchased and retired during period, shares Income Tax Authority [Domain] Income Tax Authority [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Inventory [Line Items] Concentration Risk Benchmark [Axis] Document Annual Report Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) GIAPREZA. GIAPREZA [Member] GIAPREZA Represents information pertaining to warrants acquired in the second quarter of 2020. Warrants Acquired In Second Quarter Of2020 [Member] Warrants acquired in second quarter of 2020 Share Based Compensation Arrangement By Share Based Payment Award number of annual installments Number of annual installments The number of annual installments that RSUs granted to newly appointed independent directors will vest. Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, annual interest rate Debt Instrument, annual interest rate Cumulative Effect, Period of Adoption [Axis] Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-Average Amortization Period (Years) Long-Lived Tangible Asset [Axis] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Maximum [Member] Maximum Represents the information pertaining to 2.50% convertible senior notes due 2025. Percent2.50 Convertible Debt [Member] 2025 Notes Number of warrants to be purchased under the securities purchase agreement Securities Purchase Agreement, Total Number of Warrants To Be Purchased Under Agreement The total number of warrants to be purchased under the terms of a securities purchase agreement. Purchase and sale of other investments managed by ISP FUND LP Purchase and sale of other investments managed by ISP FUND LP Purchase and sales of other investments managed by ISP Fund LP, net Purchase and sales of other investments managed by ISP Fund LP, net Purchases of capped call options associated with convertible senior notes. Purchases of Capped Call Options Associated with Convertible Senior Notes Purchases of capped call options associated with convertible senior notes due 2028 Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Summary of changes in unrecognized tax benefits Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs, Level 3 Fair Value, Inputs, Level 3 APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation Fair Value, Recurring and Nonrecurring [Table] Short-Term Debt, Type [Domain] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash and cash equivalents Warrants purchased in 2021 Warrants Purchased In2021 [Member] Represents information pertaining to warrants purchased in 2021. Debt Instrument, Convertible, Carrying Amount of Equity Component Equity component, net Term of the milestone payment on net sales Term of Milestone Payment for Net Sales Term of milestone payment for net sales. Inventory, Work in Process, Net of Reserves Work-in-process Assets, Noncurrent, Total Assets, Noncurrent Noncurrent assets Percentage of maximum royalty based on achievement of annual net product sales thresholds. Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds Percentage of maximum royalty based on achievement of annual net product sales thresholds Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method. Incremental Common Shares Attributable To Conversion Of Debt Securities, Treasury Stock Method Dilutive effect of the assumed conversion premium Estimated amortization for the year 2027 Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Capitalized Fees Paid Remaining Estimated Amortization Year Four Intangible Assets, Gross (Excluding Goodwill) Total gross carrying amount Total gross carrying amount The value of shares granted annually to independent directors upon re-election the to Board. Share Based Compensation Arrangement By Share Based Payment Award, Annual Equity Grant, Value Annual grant of shares, value Noncash Investing and Financing Items [Abstract] Supplemental Disclosure of Non-cash Investing and Financing Activities: Represents information pertaining to ISP Fund LP, an investment managed by Sarissa Capital. Isp Fund Lp [Member] ISP Fund LP Incremental Common Shares Attributable to Share-based Payment Arrangements, Total Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Forfeited (in shares) Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Contingent value rights liability Contingent value rights liability Contingent value rights liability Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti-dilutive securities Secured convertible credit agreement. Secured Convertible Credit Agreement [Member] Secured Convertible Credit Agreement Schedule of Inventory, Current [Table Text Block] Schedule of Inventory, net City Area Code Deferred State and Local Income Tax Expense (Benefit) State State Inventory, Net Total inventory Inventory Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities The value of common stock price as a percentage of conversion price. Debt Conversion, Common Stock Price to Conversion Price Ratio, Percentage Common stock price to current conversion price ratio Equity activity of noncontrolling interests in a consolidated variable interest entity (in shares) Changes To Noncontrolling Interest From A Consolidated Variable Interest Entity Shares Changes to noncontrolling interest from a consolidated variable interest entity shares. Acquired Finite-Lived Intangible Asset, Residual Value Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Debt Instrument, Repurchase Amount Portion of debt retired, carrying value PAION AG [Member] PAION AG [Member] PAION AG Represents the 2012 Equity Incentive Plan as approved by shareowners. Equity Incentive Plan2012 [Member] 2012 Equity Incentive Plan Percentage Of Royalty On Payments Received From Sublicensees Percentage of royalty on payments received from sublicensees Represents the royalty payable as a percentage of payments received from sublicensees. Business Acquisition [Line Items] Business Acquisition [Line Items] Indefinite-Lived Intangible Assets, Period Increase (Decrease), Total Indefinite-Lived Intangible Assets, Period Increase (Decrease) Measurement period adjustments for change in value of intangible assets Changes in fair values of equity and long-term investments Realized gain on equity investments Gain (Loss) on Investments, Total Gain (Loss) on Investments Changes in fair values of equity and long-term investments, net Estimated amortization for the year 2026 Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Capitalized Fees Paid Remaining Estimated Amortization YearThree Represents information pertaining to warrants acquired in the third quarter of 2020. Warrants Acquired In Third Quarter Of2020 [Member] Warrants acquired in third quarter of 2020 Customer [Domain] JAPAN Japan Selling, General and Administrative Expenses [Member] Selling, general and administrative Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Shares used to compute basic net income per share Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders Preferred stock warrants. Preferred Stock Warrants Member Preferred Stock Warrants Deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Portion of debt Instrument, repurchased. Debt Instrument, Repurchase Percentage Percentage of notes repurchased Purchases of equity method investments Payments to Acquire Equity Method Investments Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Debt instrument principal amount percentage Option Indexed to Issuer's Equity, Strike Price Strike price for the underlying number of shares (in dollars per share) Amount of increase (decrease) in estimated purchase price during measurement period. Measurement Period Adjustments, Increase Decrease In estimated Purchase Price Measurement period adjustments for change in estimated purchase price One of ImaginAb's Common Stockholders One Of Imaginabs Common Stockholder [Member] Represents information pertaining to one of ImaginAb's common stockholders. Customer three. Customer Three [Member] Customer Three Gain (Loss) on Extinguishment of Debt, Total Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Loss on extinguishment of debt Capitalized Contract Cost, Accumulated Amortization Accumulated amortization Nanolive [Member] Nanolive [Member] Nanolive Statement [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of weighted-average assumptions used to calculate estimated value of stock options Deferred tax assets unrealized losses on investment, net Deferred Tax Assets Unrealized Losses On Investment, Net Unrealized loss on investment, net Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Income Taxes [Line Items] Income Taxes No definition available. Denominator [Abstract] Denominator: Document Fiscal Period Focus Lessee, Operating Lease, Liability, to be Paid Total Total Liabilities, Noncurrent, Total Liabilities, Noncurrent Noncurrent liabilities Income (Loss) from Equity Method Investments Changes in fair values of equity method investments, net Changes in fair values of equity method investments, net Expected holding period of equity method investment. Expected Holding Period Expected holding period Financial Instruments Disclosure [Text Block] EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS Revenue from collaborative arrangements Represents information pertaining to collaborative arrangements. Collaborative Arrangements [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Statement [Line Items] Statement Subsequent Events Convertible Debt [Table Text Block] Summary of Liability and Equity Components of Convertible Notes Increase in deferred tax assets. Increase in Deferred Tax Assets Increase in Deferred Tax Assets Represents the percentage of economic interest in any future payments made under the agreements. Percentage of Economic Interest on Future Payments Under Agreements Percentage of economic interest in any future payments made under the agreements Percentage of maximum voting rights Voting Agreement, Maximum Voting Rights, Percent Represents the percentage of maximum voting rights under voting agreement. Schedule of Long-Term Debt Instruments [Table Text Block] Schedule of Debt Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions Gross decrease in tax portions from current year Debt Instrument, Fair Value Disclosure Total fair value of debt Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities (in shares) Lease, Cost Total lease costs Subsequent Event [Line Items] Warrant [Member] Warrants Long-term portion of deferred royalty obligation. Deferred Royalty Obligation, Non Current Long-term portion of deferred royalty obligation Series C warrants and Series D warrants. Series C warrants and Series D warrants [Member] Series C Warrants and Series D Warrants Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of deferred tax assets and deferred tax liabilities Cumulative Effect, Period of Adoption [Domain] Customer [Axis] Common Stock [Member] Common stock Debt Instrument [Line Items] Debt InCarda 2020 Warrants [Member] InCarda 2020 Warrants [Member] Incarda 2020 Warrants [Member] Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash balance Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Property, Plant and Equipment Useful Life [Table Text Block] Schedule of property, equipment and leasehold improvements useful lives Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense Presentation reclassification. Presentation Reclassification [Policy Text Block] Presentation Reclassification Other Assets, Current Other current assets Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value of options exercisable La Jolla La Jolla [Member] La Jolla [Member] La Jolla [Member] The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement. Securities Purchase Agreement, Amount Amount of securities purchase agreement Payments for acquire variable interest Two thousand twenty eight notes. Two Thousand Twenty Eight Notes [Member] 2028 Notes Entity Common Stock, Shares Outstanding Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Trade Accounts Receivable [Member] Receivables from Net Product Sales Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Property and equipment, net Property and equipment, net Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Consolidation, Variable Interest Entity, Policy [Policy Text Block] Variable Interest Entities Percentage of royalty payments the company is not entitled to receive. Percentage of royalty payments not entitled to receive Number of demand letters that were sent to the Company by purported stockholders. Demand Letters Sent By Stockholders Demand letters sent by stockholders Cover Cover [Abstract] Selling, General and Administrative Expense, Total Selling, General and Administrative Expense Selling, general and administrative Non Rule 10b51 Arrangement Modified Non Rule 10B51 Arr Modified Flag Non Rule 10B51 Arr Modified Flag Share Repurchase Program [Domain] Consolidated entities and acquisitions disclosure abstract. Consolidated Entities and Acquisitions Disclosure Abstract Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Current Document Fiscal Year Focus Represents information pertaining to series C preferred stock and warrants. Series C Preferred Stock And Warrants [Member] Series C preferred stock and warrants Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales. Collaborative Arrangement, Royalty Rate Defined, Level One Royalty rate for first level of annual global net sales (as a percent) Common Stock Acquired Average Cost Per Share Common Stock Acquired Average Cost Per Share Shares repurchased average price per share Income Taxes Paid, Net, Total Income Taxes Paid, Net Cash paid for income taxes Debt Instrument, Principal Payment Debt Instrument, Periodic Payment, Principal Sale of Stock [Domain] Sale of Stock [Domain] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Interest Payable, Current Accrued interest payable Capitalized Contract Cost, Net Net carrying value Capitalized fees paid, net Series C2 Preferred Stock Series C-2 Preferred Stock [Member] Series C-2 Preferred Stock member. Share-Based Payment Arrangement [Policy Text Block] Fair Value of Stock-Based Compensation Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) In Carda Convertible note. In Carda Convertible Note [Member] InCarda Convertible Note Estimated amortization for the year 2028 Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Capitalized Fees Paid Remaining Estimated Amortization Year Five Security Exchange Name Equity and long-term investments Long-term Investments, Total Long-Term Investments Accounts Receivable [Policy Text Block] Accounts Receivable Domestic Tax Authority [Member] Federal Future potential milestone payment receivable. Future Potential Milestone Payment Future potential milestone payment receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Short-term marketable securities Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Preferred Stock, Shares Issued, Total Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Authorized Preferred stock, shares authorized Schedule of Finite-Lived Intangible Assets [Table] Variable Interest Entity, Not Primary Beneficiary [Member] Variable Interest Entity, Not Primary Beneficiary Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Released RSUs/RSAs (in shares) Interest rate of deferred royalty obligation. Interest Rate of Deferred Royalty Obligation Percentage of interest rate State Current State and Local Tax Expense (Benefit) State Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating lease right-of-use assets obtained in exchange for operating lease obligations Repurchase of common stock (in shares) Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Business Acquisition, Acquiree [Domain] Convertible Debt, Current Convertible subordinated notes due 2023, net of issuance costs Legal Entity: Legal Entity [Axis] Purchases of capped calls In connection with convertible senior notes. Purchases Of Capped Calls In Connection With Convertible Senior Notes Purchases of capped calls in connection with convertible senior notes due 2028 Financial Instrument [Axis] Call Option [Member] Stock prices below $27.79 per share Weighted Average Number of Shares Outstanding, Diluted [Abstract] Shares used to compute Innoviva basic and diluted net income per share: Warrants and Rights Outstanding, Term Term of warrants Term of warrants Net amount of Marketed Products. Intangible Assets Marketed Products, Net Marketed products, net carrying amount Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Additional disclosures Entity Emerging Growth Company Proceeds from Convertible Debt Proceeds from issuance of convertible notes, net of issuance costs Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Total intrinsic value of options exercised 2023 ESPP Employee Stock Purchase Plan Twenty Twenty Three [Member] Employee Stock Purchase Plan Twenty Twenty Three [Member] Amendment Amendment Flag Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Tax Credit Carryforward, Amount Tax credit carryforward amount Sales milestone payments receivable. Sales Milestone Payments Receivable Sales milestone payments receivable Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount Impact of consolidation and deconsolidation of subsidiaries Impact of consolidation and deconsolidation of subsidiaries Schedule of Accrued Liabilities [Table Text Block] Schedule of Other Accrued Liabilities Variable Interest Entity [Line Items] CONSOLIDATED ENTITIES Capitalized Contract Cost, Amortization Amortization expense Amortization of capitalized fees paid Less: amortization of capitalized fees paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Other current assets Borrowing which takes priority over other debt securities and can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior Unsecured Convertible Notes [Member] Convertible senior notes Royalty agreement required payment for breach of agreement payment two. Royalty Agreement Required Payment For Breach Of Agreement Payment Two Maximum aggregate royalty payments Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Federal and state research credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Federal and state research credits Accounting Standards Update [Domain] Royalty financing agreement member. Royalty Financing Agreement [Member] Royalty Financing Agreement Equity Method Investment, Ownership Percentage Equity investment ownership percentage Equity method investment ownership percentage Schedule Of finite and indefinite lived intangible assets. Schedule Of Finite and Indefinite Lived Intangible Assets[Table Text Block] Summary of Accumulated Amortization of Recognized Intangible Assets License revenue recognized License Revenue Recognized License revenue recognized. Derivative, Cap Price Cap price for the underlying number of shares (in dollars per share) Finite-Lived Intangible Asset, Expected Amortization, after Year Five Future amortization expense, thereafter Variable Rate [Domain] Represents the royalty payable, as a percentage of net sales. Percentage Of Royalty Payable On Net Sales Percentage of royalty payable on net sales Entity File Number Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Private Placement Positions And Convertible Notes. Private Placement Positions And Convertible Notes [Member] Private Placement Positions And Convertible Notes Innoviva Strategic Opportunities, LLC Innoviva Strategic Opportunities Limited Liability Corporation [Member] Represents information pertaining to Innoviva Strategic Opportunities, LLC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Other long-term liabilities Portion of debt instrument face amount, exercised. Portion of Debt Instrument Face Amount, Exercised Portion of debt instrument face amount, Exercised Repayments of Unsecured Debt Payment for repurchase of convertible subordinated notes due 2023 Payment for repurchase of debt instrument In-process research and development, accumulated amortization Intangible Assets In Process Research And Development Accumulated Amortization Intangible sssets in process research and development accumulated amortization. New debt instrument interest rate after repurchase of notes member. New Debt Instrument Interest Rate After Repurchase Of Notes [Member] New Rate [Member] Deferred Tax Assets, Gross Total deferred tax assets before valuation allowance Goodwill and Intangible Assets Disclosure [Abstract] Other Liabilities, Total Other Liabilities Other Long-term debt, net of discount and issuance costs Long-Term Debt, Excluding Current Maturities Total long-term debt, net Total long-term debt, net Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at beginning of period Total cash, cash equivalents and restricted cash at end of period shown in the consolidated statements of cash flows Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows Cash and cash equivalents at end of period Balance Sheet Related Disclosures [Abstract] Balance Sheet Information Series D 1 and D 2 preferred stock and common stock. Series D 1 And D 2 Preferred Stock And Common Stock Member Series D 1 And D 2 Preferred Stock And Common Stock Share-Based Payment Arrangement [Abstract] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total liabilities assumed Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Number of outstanding RSUs and PSUs/RSAs and PSAs Convertible Subordinated Debt [Member] Convertible subordinated notes Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Debt Instrument [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Balance at the end of the period (in dollars per share) Balance at the beginning of the period (in dollars per share) Consolidated entities and acquisitions text block. Consolidated Entities and Acquisitions [Text Block] CONSOLIDATED ENTITIES AND ACQUISITIONS Deferred Tax Assets, Valuation Allowance, Total Deferred Tax Assets, Valuation Allowance Valuation allowance 2028 Long-Term Debt, Maturity, Year Five Total expenses, net Costs and Expenses Operating expenses Operating Expenses Operating expenses Total expenses Operating expenses Increase (Decrease) in Due from Related Parties, Current, Total Increase (Decrease) in Due from Related Parties, Current Receivables from collaborative arrangements Contingent sales based milestone payment. Contingent Sales Based Milestone Payment Contingent sales based milestone payment 2024 Long-Term Debt, Maturity, Year One Variable Interest Entity, Primary Beneficiary [Member] Variable Interest Entity Collaboration agreement, accumulated amortization Intangible Assets Collaboration Agreement Accumulated Amortization Intangible assets collaboration agreement accumulated amortization. Auditor Location Accrued Liabilities and Other Liabilities Total other accrued liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Collaborative Arrangement [Member] Collaboration agreement Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Armata outstanding shares percentage Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding Entity Small Business Entity Shell Company Amortization of capitalized fees and depreciation of property and equipment. Amortization of Capitalized Fees and Depreciation of Property and Equipment Amortization of capitalized fees and depreciation of property and equipment Title of Individual [Axis] Number of shares to be purchased under the securities purchase agreement Number of shares purchased under the securities purchase agreement Sale of Stock, Number of Shares Issued in Transaction Investment Type [Axis] Gate Neuroscience [Member] Gate Neuroscience [Member] Gate Neurosciences Member Debt, Long-Term and Short-Term, Combined Amount Total debt, net Total debt, net Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Exercise price of warrants Estimated amortization after 2028 Amount of estimated amortization for assets expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Capitalized Fees Paid Remaining Estimated Amortization After Year Five Capitalized fees paid weighted average useful life. Capitalized Fees Paid Weighted Average Useful Life Weighted average remaining amortization period Measurement period adjustments increase decrease in liabilities Measurement period adjustments increase decrease In liabilities Measurement Period Adjustments Increase Decrease In liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-Average Fair Value per Share at Grant Earnings Per Share [Text Block] NET INCOME PER SHARE Entity Address, Address Line One One Director. One Director [Member] One Director Revenue Benchmark [Member] Net Product Sales Finite-Lived Intangible Assets, Period Increase (Decrease), Total Finite-Lived Intangible Assets, Period Increase (Decrease) Measurement period adjustments for change in value of intangible assets Option Indexed to Issuer's Equity, Type [Axis] Armata Term Loan Armata Term Loan [Member] Armata term loan. Antidilutive Securities [Axis] Other Liabilities, Current, Total Other Liabilities, Current Other accrued liabilities Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products. G S K [Member] GSK Supplemental Balance Sheet Disclosures [Text Block] BALANCE SHEET COMPONENTS Subsequent Event Type [Domain] Interest and dividend income Interest and Dividend Income, Operating Interest and Dividend Income, Operating, Total Interest and dividend income Net Operating Loss Estimating Date Net Operating Loss Estimating Date Net operating loss estimating date Income Statement Location [Axis] La jolla pharmaceutical company member. La Jolla Pharmaceutical Company [Member] La Jolla Pharmaceutical Company Variable Lease, Cost Variable lease costs The entire disclosure for information about capitalized fees paid. Capitalized Fees Paid Disclosure [Text Block] CAPITALIZED FEES PAID 2026 Long-Term Debt, Maturity, Year Three Amortization of Debt Discount (Premium) Amortization of debt discount Net income (in shares) Profit Loss Shares Profit Loss Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Long-Term Debt, Type [Axis] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income Net income Fair Value, Nonrecurring [Member] Nonrecurring basis Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets Other assets Other assets Series C Preferred Stock [Member] Series C preferred stock Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs, Level 2 Product [Member] Net product sales Federal net operating losses estimated utilization amount. Federal Net Operating Losses Estimated Utilization Amount Federal net operating losses estimated utilization amount Equity Method Investments Total carrying value of investments Share Price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Business acquisitions of change in fair value of investment. Business Acquisitions of Change in Fair Value of Investment General Partner [Member] General Partner The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board. Share Based Compensation, Arrangement by Share Based Payment Award, Initial Equity Grant Value One time grant of shares, value Long-Term Debt, Gross Total debt Total Principal Measurement period adjustments for change in value of deferred tax liabilities Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability Debt Instrument Transaction Cost Debt instrument transaction cost Transaction cost Product and Service [Axis] Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Repurchase of common stock Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Summary of Significant Accounting Policies [Line Items] DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Title of 12(b) Security Securities purchase agreement Securities Purchase Agreement [Member] Securities purchase agreement member. Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount State income tax, net of federal benefit Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding Equity Securities [Member] Equity investment Equity Securities, FV-NI, Unrealized Gain Unrealized gain from fair value changes in equity investments Unrealized gain Payments to acquire equity securities Payments to Acquire Equity Securities, FV-NI License revenue License Revenue [Member] License revenue member Lease Contractual Term [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Maximum contributions as a percentage of employee's eligible compensation No definition available. Numerator [Abstract] Numerator: Schedule of Subsidiary or Equity Method Investee [Table] Investments [Domain] Investments [Domain] Accounting Standards Update [Axis] Treasury Stock, Common [Member] Treasury Stock Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Amortization of Debt Issuance Costs Amortization of debt issuance costs Income tax payable non current. Income Tax Payable Non Current Income tax payable, long-term Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Exercised (in shares) State and Local Jurisdiction [Member] State XACDURO XACDURO [Member] XACDURO [Member] ImaginAb Imaginab [Member] Represents information pertaining to ImaginAb. Goodwill, impairment losses Goodwill, Impairment Loss Net decrease in tax portions for 2020 Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions, Net Net amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns. Segment Reporting, Policy [Policy Text Block] Segment Reporting Represents Long-Acting Beta2 Agonist, ANORO, which is being developed and commercialized by entering into a strategic alliance with GSK Long Acting Beta2 Agonist Anoro [Member] ANORO Information related to various accounting policies of the entity. Summary of Significant Accounting Policies [Table] Long-Lived Tangible Asset [Domain] Property, Plant and Equipment, Type [Domain] Number of common stock issued description Number Of Common Stock Issued Description Number of common stock issued description. Subsequent Event [Table] Represents the royalty rate for combination products. Collaborative Arrangement Annual Royalties as Percentage of Net Sales for Combination Products Royalty rate for combination products (as a percent) Net Rentable Area Rentable square feet Business Acquisition, Share Price Acquisition share price Increase (Decrease) in Inventories, Total Increase (Decrease) in Inventories Measurement period adjustments for change in value of Inventory Inventory Change in inventory Interest Expense, Debt Total interest and amortization expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual term of options exercisable Stock Repurchase Program, Remaining Authorized Repurchase Amount Amount of shares repurchased Common Stock, Shares, Outstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-Based Payment Arrangement [Text Block] STOCK-BASED COMPENSATION Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Royalty obligation payable Accrued Royalties, Current Capitalized fee paid estimated useful life. Capitalized Fee Paid Estimated Useful Life Capitalized fees paid, estimated useful life Changes in fair values of equity and long-term investments, net Unrealized other gain loss on investments Unrealized Other Gain Loss on Investments Class of Treasury Stock [Table] n/a Convertible Debt Instrument, Liability Component [Abstract] Liability component Business Combinations Policy [Policy Text Block] Business Combination Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of available-for-sale securities measured at fair value on a recurring basis Tax Credit Carryforward [Axis] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Uncertain Tax Positions Unamortized Debt Issuance Expense Unamortized debt issuance cost Concentration Risk Type [Domain] Debt [Member] Debt Income Statement Location [Domain] Income Statement Location [Domain] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Document Type Document Type Conversion of convertible subordinated notes due 2023 (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Accounting Standards Update 2020-06 [Member] ASU 2020-06 Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets Abstract Inventory, Current [Table] Withdrawal from investment Withdrawal From Investment Withdrawal From Investment Business combination recognized identifiable assets acquired and liabilities assumed other accrued liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Accrued Liabilities Other accrued liabilities Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity. Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Weighted-Average Fair Value per Share Vested and expected to vest at the end of the period (in dollars per share) Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities No definition available. Consolidated Entities Counterparty Name [Domain] Counterparty Name [Domain] Goodwill and Intangible Assets Disclosure [Text Block] GOODWILL AND INTANGIBLE ASSETS Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Released RSUs/RSAs (in shares) Operating Lease Weighted Average Incremental Borrowing Rate Operating Lease Weighted Average Incremental Borrowing Rate Operating lease, weighted average incremental borrowing rate Limited Partners' Contributed Capital Contributed to partnership for investing Capital contribution Net loss attributable to noncontrolling interest Net Income (Loss) Available to Common Stockholders, Basic Net income attributable to Innoviva stockholders Net income attributable to Innoviva stockholders, basic Purchases of trading security managed by Isp fund Lp. Purchases of Trading Security Managed by Isp Fund Lp Purchases of trading security managed by ISP Fund LP strategic alliance - MABA program strategic alliance - MABA program Strategic alliance - MABA program Two thousand twenty three notes. Two Thousand Twenty Three Notes [Member] 2023 Notes Disclosure of accounting policy for capitalized fees paid to a related party. Capitalized Fees Paid To A Related Party [Policy Text Block] Capitalized Fees Paid Inventory, Gross, Total Inventory, Gross Inventory Deferred Tax Liabilities, Other Other Royalties payable period after first commercial sale of product. Royalties Payable Period After First Commercial Sale Of Product Royalties payable period after first commercial sale of product Qualified Financing [Member] Qualified Financing [Member] Qualified Financing Net Cash Provided by (Used in) Financing Activities Net cash used in financing activities Estimated amortization for the year 2024 Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Three Lessee, operating lease, liability, to be paid, after year three. Entity Filer Category Deferred Tax Assets, Tax Credit Carryforwards, Research Research and development tax credit carryforwards Maximum amount the employee may contribute of employee's eligible compensation. Share-Based Compensation Arrangement By Share-Based Payment Award Maximum Amount As A Contribution Of Eligible Compensation Maximum value of shares an employee may purchase in a calendar year Balance Sheet Location [Domain] Increase (Decrease) in Accrued Liabilities, Total Increase (Decrease) in Accrued Liabilities Accrued personnel-related expenses and other accrued liabilities Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc [Member] Paratek Pharmaceuticals, Inc Geographic Concentration Risk [Member] Geographic Concentration Risk Purchases of Equity Investments Managed by Isp Fund Lp Purchases of Equity Investments Managed by Isp Fund Lp Purchases of equity investments managed by ISP Fund LP Variable Rate [Axis] Purchases of trading securities Payments to Acquire Marketable Securities, Total Payments to Acquire Marketable Securities Factors affecting comparability. Factors Affecting Comparability Policy [Text Block] Factors Affecting Comparability Investment-related expenses, net of investment-related income Investment Income, Investment Expense Innoviva's Common Stock Member Innoviva Common Stock Member Innoviva's Common Stock Liabilities, Total Liabilities Total liabilities Number of customers. Number Of Customers Number of customers Property, Plant and Equipment [Table] Investment Income, Interest and Dividend Investment Income, Interest and Dividend, Total This member stands for Sarissa Capital. Sarissa Capital Management Lp [Member] Sarissa Capital Finite-Lived Intangible Asset, Useful Life Marketed products, Useful Life Software and computer equipment Software And Computer Equipment [Member] Software and computer equipment Customer one. Customer One [Member] Customer One State net operating losses estimated utilization amount. State Net Operating Losses Estimated Utilization Amount State net operating losses estimated utilization amount Consolidated Entities [Axis] Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference Intangible Assets, Net (Excluding Goodwill) Net carrying amount Intangible assets Net Income (Loss) Net income attributable to Innoviva stockholders Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Interest Expense, Total Interest Expense Interest expense Interest expense Second Note Amendment Agreement Second Note Amendment Agreement [Member] Second note amendment agreement. Repayments of Convertible Debt Payment towards convertible promissory note Capitalized fees paid future amortization. Capitalized Fees Paid Future Amortization [Abstract] Capitalized Fees paid, Future amortization Convertible debt investment Convertible Debt [Member] Name Of Event [Axis] Name Of Event [Axis] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Deferred tax liabilities Statement of Financial Position [Abstract] Two thousand twenty five notes. Two Thousand Twenty Five Notes [Member] Two Thousand Twenty Five Notes [Member] 2025 Notes Area of Real Estate Property Lease space Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares) Weighted Average Number of Shares Outstanding, Diluted Shares used to compute diluted net income per share Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of differences between expected U.S. federal statutory income tax to income tax expense Debt Instrument, Repurchased Face Amount Debt Instrument, Repurchased Face Amount Portion of debt retired, face value Deferred Federal Income Tax Expense (Benefit) Federal Federal Represents information pertaining to InCarda. Incarda [Member] InCarda Business combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right-of-Use Assets Right-of-use assets Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Operating Lease, Weighted Average Remaining Lease Term Operating lease, Weighted average remaining lease term Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Purchase price as a percentage of fair market value of stock Use of Estimates, Policy [Policy Text Block] Use of Management's Estimates George Washington University. George Washington University [Member] George Washington University Income Tax Disclosure [Text Block] INCOME TAXES New principal amount. New Principal Amount [Member] New Principal Amount Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets 'Total assets acquired Net investment-related income (expense) earned (incurred) Net Investment Related Income Expense Earned Inccured Net investment related income (expense) earned (inccured). Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance at the end of the period (in dollars per share) Balance at the beginning of the period (in dollars per share) Additional cash investment Purchases of equity and long term investments Payments to Acquire Long-Term Investments Initial contribution Finite-Lived Intangible Assets [Line Items] Clinical development and regulatory milestones amount payable. Clinical Development And Regulatory Milestones Amount Payable Clinical development and regulatory milestones amount payable Extended expiration date. Extended Expiration Date Extended expiration date Loan Restructuring Modification [Axis] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net income per share Subscription agreement one-time milestone payment on net sales Subscription Agreement One-time Milestone Payment on Net Sales Subscription agreement one-time milestone payment on net sales. Innoviva [Member] Innoviva [Member] Innoviva [Member] Term of the milestone payment on first commercial sale Term of Milestone Payment for Commercial Sale Term of milestone payment for commercial sale. Interest Expense, Debt, Excluding Amortization Contractual interest expense Valuation Approach and Technique [Axis] Disaggregation of Revenue [Line Items] Revenue Recognition and Collaborative Arrangements Income Tax Authority [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-Dilutive Securities Fair Value Disclosures [Abstract] Current Income Tax Expense (Benefit) Total current Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Deferred revenue Estimated amortization for the year 2025 Capitalized Fees Paid Remaining Estimated Amortization Year Two Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities Other Long Term Liabilities Amortization of fair value adjustments of cost of products sold. Amortization of Fair Value Adjustments of Cost of Products Sold Amortization of fair value adjustments of Cost of products sold Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Increase (decrease) in deferred tax liabilities Increase (decrease) in deferred tax liabilities. Increase (Decrease) in Deferred Tax Liabilities Measurement period adjustments increase decrease in deferred tax liabilities Capitalized Contract Cost, Gross Milestone fees paid Gross carrying value Cost Reimbursement Cost Reimbursement [Member] Cost reimbursement. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Released RSUs and RSAs (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Granted (in shares) Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Accrued personnel-related expenses Business Acquisition [Axis] Deferred Revenue, Current, Total Deferred Revenue, Current Deferred revenue Goodwill, Period Increase (Decrease), Total Goodwill, Period Increase (Decrease) Measurement period adjustments for change in value of goodwill Decrease in goodwill Royalty agreement required payment for breach of agreement payment one. Royalty Agreement Required Payment For Breach Of Agreement Payment One Required payment for breach of agreement, payment one Income Tax Disclosure [Abstract] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Consolidated entities and acquisitions. Consolidated Entities and Acquisitions [Line Items] Consolidated Entities and Acquisitions [Line Items] Finite-Lived Intangible Assets by Major Class [Axis] Zai Lab. Zai Lab [Member] Zai Lab Operating Loss Carryforwards, Total Operating Loss Carryforwards Net operating loss carryforwards Harvard University. Harvard University [Member] Harvard University